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plasma by LC-MS/MS and its application to a
pharmacokinetic study in rats
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Background: Yakuchinone A has a plethora of beneficial biological effects. However, the pharmacokinetic (PK) data
of yakuchinone A still remain unknown so far. Furthermore, the quantification of yakuchinone A in biological
samples has not been reported in the literature. Therefore, in the present study we aimed to develop a new
method for the fast, efficient and accurate assessment of yakuchinone A concentration in plasma, as a means for
facilitating the PK evaluation of yakuchinone A.
Results: A liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) method was
developed and validated for the determination of yakuchinone A in rat plasma. Mass spectrometric and chromatographic
conditions were optimized. Plasma samples were pretreated by protein precipitation with methanol. LC separation
was performed on a Phenomenex Luna C18 column with gradient elution using a mobile phase consisting of
methanol–water containing 0.5 mM formic acid (HCOOH) at a flow rate of 0.28 mL/min. ESI-MS spectra were
acquired in positive ion multiple reaction monitoring mode (MRM). The precursor-to-product ion pairs used for
MRM of yakuchinone A and yakuchinone B were m/z 313.1→ 137.0 and 311.2→ 117.1, respectively. Low concentration
of HCOOH reduced the ion suppression caused by matrix components and clearly improved the analytical sensitivity.
Yakuchinone A showed good linearity over a wide concentration range (r > 0.99). The accuracy, precision, stability and
linearity were found to be within the acceptable criteria. This new method was successfully applied to analyze the rat
plasma concentration of parent yakuchinone A after a single oral administration of SuoQuan capsules. Low systemic
exposure to parent yakuchinone A was observed.
Conclusion: The proposed method is sensitive and reliable. It is hoped that this new method will prove useful for the
future PK studies.
Keywords: Yakuchinone A, LC-MS/MS, Matrix effects, HCOOH, Pharmacokinetic study, SuoQuan capsulesBackground
Yakuchinone A [1-(4′-hydroxy-3′-methoxyphenyl)-7-
phenyl-3-heptanone] was isolated from the fruits of
Alpinia oxyphylla Miq. (Zingiberaceae) [1]. In East
Asian traditional medicine, these edible fruits are
widely used for treating dyspepsia, diarrhea, polyuria, and
gastralgia [2]. Pharmacological studies both in vitro and
in vivo have confirmed that yakuchinone A has a plethora
of beneficial biological effects. Yakuchinone A strongly in-
hibits prostaglandin biosynthesis in vitro [3,4]. Yakuchinone* Correspondence: cy.chen508@gmail.com; jqzhang2011@163.com
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otherwise stated.A has inhibitory effects on phorbol ester-induced inflam-
mation and skin carcinogenesis in mice and oxidative stress
in vitro [5]. Yakuchinone A induces apoptotic death in
cultured human promyelocytic leukemia cells [6,7].
Moreover, yakuchinone A inhibits the expression of
cyclooxygenase-2 and of inducible nitric oxide synthase,
as well as the expression of tumor necrosis factor-alpha
mRNA in mouse skin [5,8]. These findings demonstrate
that this compound has anti-inflammatory properties.
In addition, the compound suppresses the spontaneous
calcium spikes and contraction in isolated portal veins
of mice [9]. However, in our lab, we have found that
yakuchinone A significantly induces the contraction of
rat detrusor muscles in vitro.l Ltd. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
main/zero/1.0/) applies to the data made available in this article, unless
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logical research of botanical product and the appropriate
PK properties are a prerequisite for the compound to
play a role pharmacologically. However, the PK data of
yakuchinone A still remain unknown so far. To the best
of our knowledge, the quantification of yakuchinone A
in biological samples has not been reported in the litera-
ture. Thus, we sought to develop a new method for the
fast, efficient and accurate assessment of yakuchinone A
concentration in plasma, as a means for facilitating the
PK evaluation of yakuchinone A. Here we report the
development and full validation of a rapid and sensitive
method based on high performance liquid chromatog-
raphy with tandem mass spectrometry (LC-MS/MS) for
determination of yakuchinone A in rat plasma, as well as
the use of this method to analyze samples obtained during
a single oral PK study in Sprague-Dawley (SD) rats.
Experimental
Chemicals and reagents
Reference standards of yakuchinone A and B (used as
internal standard, IS) were purchased from Chenfun
Medical Technology (Shanghai) Co., Ltd. (Shanghai, China).
The purity of these compounds was > 98%. HPLC-grade
methanol and acetonitrile were products of Sigma-Aldrich
(St Louis, MO, USA). HPLC-grade HCOOH was pur-
chased from Aladdin Industrial Inc. (Shanghai, China).
HPLC-grade water was prepared by double-distillation of
deionized water. The other chemical reagents of analytical
grade or better were obtained from Hainan YiGao
Instrument Co., Ltd (Haikou, China). The utilized
SuoQuan capsules are commercially available A. Oxyphyllae
Fructus products. The SuoQuan capsules were purchased
from Hansen Pharm. (lot no.110602, expiration: 2013/
05; Chinese SFDA ratification no.Z19991039; Yiyang,
Hunan Province, China) and each capsule contains 0.3 g
of solid.
The main constituents occurring in SuoQuan capsules
have been measured by LC-MS/MS [10]. Each capsule
contained the following amounts of phytochemicals:
nootkatone (142 μg), yakuchinone A (162 μg), yakuchinone
B (7.28 μg), oxyphyllacinol (12.7 μg), boldine (63.0 μg),
norisoboldine (388 μg), linderane (3.90 μg), isolinderalactone
(2103 μg), atractylenoide III (1.73 μg), tectochrysin
(8.00 μg), izalpinin (1.70 μg), chrysin (5.12 μg),
apigenin-4′,7-dimethyl ether (11.5 μg) and kaempferide
(1.25 μg), respectively.
Animal study
All rat experiments were performed in accordance with
the Institutional Animal Care and Use Committee at the
Hainan Medical University (Haikou, China), as well
as the Guidance for Ethical Treatment of Laboratory
Animals (The Ministry of Science and Technology ofChina, 2006). Male SD rats (310–330 g) were purchased
from DongChuang Laboratory Animal Service Depart-
ment (Changsha, China). Rats were maintained under
controlled temperature of 24 ± 2°C and relative humidity
of 60% ± 10% with a 12-h light/dark cycle. Commercial
rat chow was available ad libitum except for an over-
night fasting period before dosing. All rats had free
access to water.
For the PK study, three rats received a single oral
ingestion of SuoQuan capsules at 5.7 g/kg via gavage.
Before use, the drugs enclosed in the hard “shell” were
suspended in 0.5% w/v sodium carboxymethyl cellulose.
Serial blood samples (~ 0.3 ml each at 5, 10, 20 and
30 min, 1, 2, 4, 6, 8, 11 and 24 h post-dosing) were
collected in heparinized tubes. The blood samples were
centrifuged to obtain the plasma fractions that were
frozen at –70°C until analysis.
Plasma PK parameters were estimated by a noncom-
partmental method using the Kinetica 2000 software
package (version 3.0; Innaphase Corp., Philadelphia, PA).
The Cmax and the Tmax were observed values with no
interpolation. The area under concentration-time curve
up to the last measured time point (AUC0→t) was calculated
by the trapezoidal rule. The AUC0→∞ was generated by
extrapolating the AUC0→t to infinity.Plasma sample preparation
Plasma samples (50 μL) were treated with 150 μL methanol
containing the IS (300 ng/mL). The mixture was mixed by
vortex-shaking for 10 min and centrifuged at 13, 000 × g
for 10 min. 10 μL of supernatant were applied to LC -MS/
MS analysis.LC-MS/MS conditions
The LC-MS/MS system consisted of an AB-SCIEX API
4000+ mass spectrometer (Toronto, Canada) interfaced
via a Turbo V ion source with a Shimadzu Prominence
UFLC chromatographic system (Shimadzu Corporation,
Kyoto, Japan), which is equipped with two LC-20 AD
pumps, a model DGU-20A3R degasser unit, a SIL-20A
HT autosampler and a CTO-20A column oven. The AB-
SCIEX Analyst software packages were used to control
the LC-MS/MS system, as well as for data acquisition
and processing.
Chromatographic separations of prepared samples
were achieved using a phenomenex W Luna C18 column
(5 μm, 2.0 mm i.d × 50 mm) maintained at 40°C. The LC
mobile phases (delivered at 0.28 mL/min) included water
containing 0.5 mM HCOOH for solvent A and methanol
containing 0.5 mM HCOOH for solvent B. A specially
designed LC binary gradient elution was performed and
the gradient program was as fallows: 0–1 min at 0% B;
from 0% B to 80% B in 0.01 min; from 80% B to 100% B
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2.5 min.
The mass spectrometer was operated in the positive ion
ESI mode with MRM for all the analytes. The pneumatic-
ally nebulized ESI spraying was achieved by using inner
coaxial nebulizer N2 gas (GS1) of 55 psi through a
TurboIonSpray probe, a high voltage of + 5.0 kV applied to
the sprayer tip, and heated dry N2 gas (GS2) of 55 psi at
500°C from two turbo heaters adjacent to the probe. To
prevent solvent droplets from entering and contaminating
the ion optics, a curtain N2 gas of 45 psi was applied
between the curtain plate and the orifice. The collision gas
(CAD) flow was set at level 7. The precursor-to-product
ion pairs (Figure 1) used for MRM of yakuchinone A and
B were m/z 313.1→ 137.0 and 311.2→ 117.1, respectively,
with a scan time of 30 ms for each ion pair.
Construction of standard curves
Standard curves were constructed within the plasma
concentration range 1 to 2000 ng/mL by plotting theFigure 1 Typical MS/MS product ion spectra of yakuchinone A and B.
source were compared for both analytes. The chemical structures and MS/
respectively. The experiment was performed under Manually Tuning mod
(1 μg/ml) at a rate of 5 μL/min.peak area ratios (Y) of the analytes to the IS against the
corresponding nominal plasma concentrations of the
analyte (X, ng/mL) and the 1/X2 was used as a weighting
factor.
Method validation
Assay validation was carried out according to the US
FDA guidance on bioanalytical method validation (http://
www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf)
to demonstrate that the newly developed bioanalytical
method was reliable for the intended applications. The
quality control samples were prepared from an independent
weighing of the reference standard.
Results and discussion
Optimization of mass spectrometric and chromatographic
conditions
Positive or negative ionization methods were tested
and compared to obtain good specificity and sensitivity
for yakuchinone A and IS determination. As shown inThe intensities of the [M + H]+or the [M-H]- ions produced in the ESI
MS conditions are shown on the upper and the lower panel,
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Figure 2 MS/MS parameters and LC conditions optimization. For each MS/MS parameter optimization, the other normal LC-MS/MS
conditions were used, including ion source parameters (collision gas, level 4; curtain gas, 25 psi; Gas 1, 55 psi; Gas 2, 55 psi; ionspray voltage, 5.5
kv; temperature, 550°C) and LC parameters (flow rate, 0.30 mL/min; column oven temperature, 40°C). Finally, the resulting optimized parameters
were combined and the signal intensity of the test yakuchinone A (blue open diamond symbol and blue solid diamond symbol) and B (red open
circle symbol and red solid circle symbol) were compared with those of data under premature LC-MS/MS conditions.
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than negative ESI by infusing an approximately 1 μg/mL
standard stock solution of yakuchinone A and IS in
acetonitrile using a Harvard infusion pump (Harvard
Apparatus, South Natick, MA, USA). During a directinfusion experiment, the mass spectra for yakuchinone
A and IS revealed peaks at m/z 313.1 and 311.2, respect-
ively as protonated molecular ions [M +H]+. The prod-
uct ion mass spectrum for yakuchinone A shows the
formation of characteristic product ion at m/z 137.0. For
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http://journal.chemistrycentral.com/content/8/1/2IS, the m/z 117.1 fragment was dominant and was there-
fore used for quantification.
On the basis of the optimized ionization mode, the
mass spectrometric parameters including the collision
gas (CAD), curtain N2 gas (CUR, psi), GS1 (psi), GS2
(psi), TurboIonSpray probe voltage (kv), and ion source
temperature (°C) were further optimized in order to get
the richest relative abundance of precursor-to-product
ions. As shown in Figure 2, the parameters CAD, CUR
and temperature significantly influenced the peak areas
of yakuchinone A and IS. The lower panel of Figure 1
shows the optimized MS/MS compound parameters
(left) and ion source parameters (right). At the end, the
highest peak area for molecular ion of the analyte was
achieved when the optimized compound parameters and
























Figure 3 LC-MS/MS chromatograms for a typical blank rat plasma sam
yakuchinone B (IS, panel B), a mixture of standard yakuchinone A and
rat 5 min after receiving a single oral dose of Suoquan capsules at 5.To achieve the efficient separation of yakuchinone
A and IS, different mobile phases (methanol/water
system and acetonitrile/water system) were tested.
Compared with methanol used as organic phase, the
peak shape was widened and the peak area decreased
significantly (~ 10-fold). However, the test mobile
phase system had little influence on the retention time.
Therefore, methanol/water system was chosen as the
mobile phase. In addition, as the mobile phase flow
rate and column oven temperature increased, the peak
area, as well as the corresponding retention time,
of yakuchinone A and IS decreased (Figure 2, the
bottom panels). The best separation was obtained
when gradient elution was performed and column



















ple (panel A), the same blank plasma sample spiked with
IS (panel C), and an IS-spiked plasma sample obtained from a
7 g/kg (panel D).




Peak area (× 104)
Intra-day Inter-day
Day 1 Day 2 Day 3
Mean ± SD RSD Accuracy Mean ± SD RSD Accuracy Mean ± SD RSD Accuracy Mean ± SD RSD Accuracy
Yakuchinone A
4 5.72 ± 0.12 2.11% 101% 5.43 ± 0.16 2.98% 94.1% 5.31 ± 0.31 5.90% 91.5% 5.49 ± 0.27 4.89% 95.4%
80 94.6 ± 1.6 1.71% 102% 90.3 ± 2.5 2.81% 97.7% 93.7 ± 1.7 1.78% 101% 92.9 ± 2.7 2.87% 101%
800 818 ± 6 0.77% 89.6% 784 ± 4 0.46% 85.8% 813 ± 12 1.41% 89.0% 805 ± 17 2.13% 88.1%
IS
80 49.3 ± 1.7 3.52% 102% 48.7 ± 1.6 3.30% 101% 46.7 ± 1.5 3.23% 96.3% 48.2 ± 1.9 3.93% 99.6%
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Specificity and selectivity
Selectivity was investigated by comparing the chromato-
grams of six different blank rat plasma samples with
the corresponding spiked plasma samples with known
concentrations of the analytes. The retention times for
yakuchinone A and IS were about 4.00 and 4.05 min,
respectively. The limit of detection (LOD) and limit of
quantification (LOQ) were the concentrations at which
the analyte signal-to-noise ratios were 3:1 and 10:1,
respectively. They were achieved by serial dilution of
spiked plasma sample solutions using the described LC-
MS/MS conditions. The LOD and LOQ of yakuchinone
A were 0.05 and 0.5 ng/mL, respectively. A representa-
tive chromatogram is illustrated in Figure 3, including
blank plasma, spiked plasma sample with analytes in
LLOQ level and IS, as well as a plasma sample from rat
5 min after receiving a single oral dose of Suoquan
capsules. No peaks from endogenous biological matrix
or other source were observed at the same retention
time of Yakuchinone A and IS in any of the blank
plasma, which suggested that the developed procedure
was specific and selective.
Linearity and LLOQ
The matrix-based calibration curve (Y = 0.00202X +





Set 1 Set 2
Mean ± SD RSD Mean ± SD RSD Mean ±
Yakuchinone A
4 7.45 ± 0.15 2.04% 6.43 ± 0.04 0.70% 5.18 ± 0
80 113 ± 6 5.05% 111 ± 3 2.59% 79.9 ± 1
800 930 ± 61 6.56% 884 ± 19 2.11% 789 ± 12
IS
80 80.7 ± 7.8 9.65% 89.7 ± 1.9 2.16% 52.7 ± 21–2000 ng/mL for yakuchinone A with correlation
coefficient of 0.997. The LLOQ samples of six different
rat plasma independent of the calibration curves were
analyzed. The LLOQ was 1 ng/mL (S/N > 10), with a
precision of 5.88% and accuracy of 97.0% for yakuchi-
none A.
Precision and accuracy
As shown in Table 1, the newly developed method gave
good precision and accuracy with the intra- and inter-
day assays. The intra-day accuracy ranged from 85.8% to
102% for yakuchinone A and from 96.3% to 102% for IS;
as well as the inter-day accuracy ranged from 88.1% to
101% for yakuchinone A and 96.6% for IS, respectively.
The intra- and inter-day precisions were within
0.46%–5.90% for yakuchinone A and 3.23%–3.93%
for IS, respectively. The results for both intra- and inter-day
accuracy and precision were found to be within the
acceptable criteria and allowed the accurate assay of
the analytes in rat plasma.
Extraction recovery and matrix effect
Extraction efficiencies and matrix effects were examined
in quintuplicate by comparing analyte peak areas of
across three different sample sets [11,12]. In set 1, ana-
lytes were dissolved in matrix component-free reconsti-
tution solvent. In set 2, analytes were added into fivenone A and IS in rat plasma (n = 5)
k area (× 104)
Set 3 Matrix effect Extraction efficiency
SD RSD Mean (%) RSD (%) Mean (%) RSD (%)
.12 2.28% 86.3 1.95 80.5 2.30
.2 1.56% 98.5 6.95 71.7 2.89
1.50% 95.5 8.54 89.2 1.19
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Peak position Peak position
Max. 1.9e4 cps. Max. 2.1e4 cps.
Max. 1.5e4 cps. Max. 1.3e4 cps.
Max. 2.9e4 cps. Max. 2.4e4 cps.
Max. 3.4e4 cps. Max. 1.9e4 cps.
Max. 3.4e4 cps. Max. 1.9e4 cps.
Max. 3.9e4 cps. Max. 1.9e4 cps.
Max. 2.8e4 cps. Max. 1.9e4 cps.
Max. 2.8e4 cps.Max. 2.5e4 cps.
Max. 1.2e4 cps. Max. 1.2e4 cps.
Figure 4 Comparison of infusion chromatograms in the positive ESI ion mode using the mobile phases modified with different
concentration of HCOOH under the gradient elution condition.






























Figure 5 Effect of HCOOH mobile phase concentration on the
yakuchinone A (blue open diamond symbol) and B (red open
circle symbol) signal intensity in positive-ion mode.
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rats. In set 3, analytes were added to plasma from un-
treated plasma and then extracted. The absolute matrix
effect and extraction recovery were calculated as follows:
Absolute matrix effect = (Mean peak area)set 2 ⁄ (Mean
peak area)set 1
Extraction efficiency = (Mean peak area)set 3 ⁄ (Mean
peak area)set 2
This post-extraction spike method proposed by Matus-
zewski et al. [11] provides a quantitative understanding of
the level of matrix effect observed for specific analytes. In
the present study, the extraction recoveries of the quality
control samples for yakuchinone A and IS are summa-
rized in Table 2. The extraction recovery ranged from 72%
to 89% for yakuchinone A and 59% for IS, respectively,
which suggested that the extraction recovery of both ana-
lytes was efficient, consistent and reproducible. Mean-
while, Table 2 shows the results of matrix effects for bothTable 3 Stability of the yakuchinone A and IS in rat plasma (n
Peak ar
Short-term stability (4 h at room temperature) Autosampler st
Mean ± SD RSD Mean ±
Yakuchinone A
4 5.04 ± 0.18 3.59% 5.61 ± 0
80 79.7 ± 1.8 1.49% 96.4 ± 1
800 829 ± 82 9.86% 834 ± 1
IS
80 49.5 ± 1.5 3.04% 51.1 ± 1analytes. The average matrix effects at three different con-
centrations were 86.3–98.5% for yakuchinone A and 112%
for IS. However, we could not conclude whether the
unseen biological matrix significantly influenced the
ionization of analytes and IS because the mobile phases
were added with low concentration of HCOOH (0.5 mM),
which actually impacted the matrix effects, ESI efficiency
and capacity [12-16].
On the other hand, we employed a post-column infusion
method to assess the matrix in order to achieve the direct
visualization of the nature, chromatographic profile and
the extent of the interference caused by matrix compo-
nents [17,18]. The post-column infusion method provides
a qualitative assessment of matrix effects, identifying chro-
matographic regions most likely to experience matrix ef-
fects. Figure 4 shows the infusion chromatograms obtained
in the positive ESI ion mode, exhibiting the matrix effect of
methanol-precipitated rat plsma on the response to post-
column infusion of yakuchinone A and IS. The co-eluting
matrix components caused significant ion suppression of
both yakuchinone A and IS (upper panel, HCOOH free)
and the signal intensity could not come back to the initial
level at the end of the elution time program. Therefore, the
peak areas of both analytes were diminished after multiple
injections under optimized LC-MS/MS conditions. How-
ever, the inclusion of HCOOH in the LC mobile phase
reduced suppression of the Yakuchinone A and IS signal in
a concentration-dependent manner (Figure 4). Concentra-
tions of HCOOH up to 0.1 mM had minimal effect, while
concentrations of 0.5-100 mM resulted in comparable
matrix effect reduction. The best result appeared to be
achieved with the 0.5 mM HCOOH-modified mobile
phase, which exhibited significant matrix suppression only
during a 1-minute window early in the run (Figure 5).
Stability
The stabilities of yakuchinone A and IS tested to reflect
situations likely to be encountered during actual sample
handling and analysis. As summarized in Table 3, the er-
rors in yakuchinone A and IS peak area values for all the
test samples were between 1.49% and 13.2% of nominal,= 5)
ea (× 104)
ability (8 h at room temperature) Freeze-thaw stability (3 cycles)
SD RSD Mean ± SD RSD
.21 3.72% 5.18 ± 0.13 2.60%
.9 2.01% 80.4 ± 7.9 9.84%
8 2.22% 801 ± 106 13.2%
.7 3.35% 45.7 ± 4.5 9.76%
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± 15%). These findings demonstrate that the yakuchi-
none A and IS were all acceptably stable under the
tested conditions.
Pharmacokinetic application
Finally, the newly developed method was applied to rat PK
study of yakuchinone A. In a pilot rat study, yakuchinone
A, boldine, norisoboldine and isolinderalactone could be
detected in the plasma after a single oral administration of
SuoQuan capsules at 5.7 g/kg. In the current study, we
focused on the bioanalytical analysis of yakuchinone A, and
therefore, the yakuchinone B was used as the internal
standard. We found that plasma parent yakuchinone A ob-
served only up to 0.5 h after dosing and the concentrations
were quite low with the mean Cmax at 4.62 ng/mL. The
plasma parent yakuchinone A peaked at 0.083 h postdose
and declined rapidly (mean MRT value, 0.63 h). The mean
AUC0→t value was 0.72 h · ng/mL. Meanwhile, the signifi-
cant individual differences were observed. Like the situation
of curcumin [19,20], parent yakuchinone A exhibits a low
systemic exposure in rats and the absorbed yakuchinone A
may undergo rapid first-pass elimination.
Conclusion
Here, we developed and validated an analytical method
based on LC-MS/MS to measure yakuchinone A concen-
tration in rat plasma treated by a simple protein
precipitation procedure. The newly developed method was
simple, sensitive and reliable. Mass spectrometric and
chromatographic conditions were optimized. Low concen-
tration of HCOOH reduced the ion suppression caused by
matrix components and clearly improved the analytical
sensitivity. This new method was successfully applied to
analyze the rat plasma concentration of parent yakuchi-
none A after a single oral administration of SuoQuan
capsules, an herbal medicine containing the fruits of A.
oxyphylla Miq. Low systemic exposure to parent yakuchi-
none A was observed. It is hoped that this new method will
be useful for the future PK studies of SuoQuan capsules.
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